| Literature DB >> 24659738 |
Célia Nogueira1, Maria Chiara Meschini2, Claudia Nesti2, Paula Garcia3, Luisa Diogo3, Carla Valongo1, Ricardo Costa4, Arnaldo Videira5, Laura Vilarinho1, Filippo M Santorelli6.
Abstract
Succinyl-coenzyme A synthase is a mitochondrial matrix enzyme that catalyzes the reversible synthesis of succinate and adenosine triphosphate (ATP) from succinyl-coenzyme A and adenosine diphosphate (ADP) in the tricarboxylic acid cycle. This enzyme is made up of α and β subunits encoded by SUCLG1 and SUCLA2, respectively. We present a child with severe muscular hypotonia, dystonia, failure to thrive, sensorineural deafness, and dysmorphism. Metabolic investigations disclosed hyperlactacidemia, moderate urinary excretion of methylmalonic acid, and elevated levels of C4-dicarboxylic carnitine in blood. We identified a novel homozygous p.M329V in SUCLA2. In cultured cells, the p.M329V resulted in a reduced amount of the SUCLA2 protein, impaired production of mitochondrial ATP, and enhanced production of reactive oxygen species, which was partially reduced by using 5-aminoimidazole-4-carboxamide ribonucleotide in the culture medium. Expanding the array of SUCLA2 mutations, we suggested that reactive oxygen species scavengers are likely to impact on disease prognosis.Entities:
Keywords: SUCLA2; encephalomyopathy; methylmalonic aciduria; mitochondrial DNA depletion; succinate-coenzyme A ligase
Mesh:
Substances:
Year: 2014 PMID: 24659738 DOI: 10.1177/0883073814527158
Source DB: PubMed Journal: J Child Neurol ISSN: 0883-0738 Impact factor: 1.987